Key result
Targeting extracellular CIRP with the XA-CIRP aptamer reduced CIRP-induced pancreatic acinar cell injury in vitro and L-arginine-induced pancreatic injury and inflammation in vivo.
Why the study?
Severe acute pancreatitis carries a high mortality rate, and the role of cold-inducible RNA binding protein in its pathogenesis and the therapeutic potential of targeting it remained to be explored.
Does targeting extracellular CIRP with XA-CIRP reduce pancreatic injury and inflammation in acute pancreatitis models?
Does targeting extracellular CIRP with XA-CIRP reduce pancreatic injury and inflammation in acute pancreatitis models?
Targeting extracellular CIRP with X-aptamers may be a promising therapeutic strategy to treat acute pancreatitis.
Answers are grounded in this paper and cite their sources.
Should not change practice in acute pancreatitis; leaves open CIRP-targeted therapy for future human trials.
Severe acute pancreatitis (AP) is associated with a high mortality rate. Cold-inducible RNA binding protein (CIRP) can be released from cells in inflammatory conditions and extracellular CIRP acts as a damage-associated molecular pattern. This study aims to explore the role of CIRP in the pathogenesis of AP and evaluate the therapeutic potential of targeting extracellular CIRP with X-aptamers. Our results showed that serum CIRP concentrations were significantly increased in AP mice. Recombinant CIRP triggered mitochondrial injury and ER stress in pancreatic acinar cells. CIRP −/− mice suffered less severe pancreatic injury and inflammatory responses. Using a bead-based X-aptamer library, we identified an X-aptamer that specifically binds to CIRP (XA-CIRP). Structurally, XA-CIRP blocked the interaction between CIRP and TLR4. Functionally, it reduced CIRP-induced pancreatic acinar cell injury in vitro and L-arginine-induced pancreatic injury and inflammation in vivo . Thus, targeting extracellular CIRP with X-aptamers may be a promising strategy to treat AP.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied Acute pancreatitis. XA-CIRP (X-aptamer targeting CIRP) was evaluated on Pancreatic injury and inflammation. Targeting extracellular CIRP with the XA-CIRP aptamer reduced CIRP-induced pancreatic acinar cell injury in vitro and L-arginine-induced pancreatic injury and inflammation in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: